Abstract:FHL2, a member of LIM-only protein family, plays an important role in transcription regulation, apoptosis, cancer development and progression. In this study, a mammalian transcription activation system was constructed by using DNA binding domain(DBD) of GAL4 and luciferase reporter gene with DBD binding sequence, and used for mapping of FHL2 transcription activation domain. First, the coding sequence of GAL4-DBD was inserted into expression vector pcDNA3, generating the pDBD recombinant plasmid, then the wild-type FHL2 and its mutants were fused in-frame with GAL4-DBD, resulting in expression vectors for wild-type FHL2 and its mutants. All of the recombinant plasmids were transfected into 293T cells. Western blot assay showed that all of the fusion proteins were expressed. The analysis of FHL2 transcription activation properties by using the GAL4-luciferase reporter gene indicated that wild-type FHL2 had activation activity in both 293T and MCF-7 cells. The deletion of the half LIM domain at the N-terminus severely impaired the capacity of FHL2 to stimulate transcription. The mutant lacking the LIM domain at the C-terminus was totally inactive, while the deletion of two LIM domains at the C-terminus partially recovered its ability to stimulate transcription. The deletion of the second LIM domain at C-terminus did not alter the activation capacity of FHL2. These results suggest that the last LIM domain at the C-terminus of FHL2 is critical for its transcription activation function, the second LIM domain at the C-terminus may be a negative regulation region, but this negative regulation depends on the last LIM domain. Mapping of transcription activation domain of FHL2 lays solid basis for further study on various FHL2 functions.

Four and a Half LIM Protein 2 (FHL2) Negatively Regulates the Transcription of E-cadherin Through Interaction with Snail1.

Four-and-a-half LIM Protein 2 Promotes Invasive Potential and Epithelial-Mesenchymal Transition in Colon Cancer.

FHL2 activates β-catenin/Wnt signaling by complexing with APC and TRIM63 in lung adenocarcinoma

Four and a Half LIM Domains Protein 1 Can Be As a Double-Edged Sword in Cancer Progression

Synergistic repression of estrogen receptor transcriptional activity by FHL2 and Smad4 in breast cancer cells.

Fhl1 Interacts With Oestrogen Receptors And Regulates Breast Cancer Cell Growth

Four and a Half LIM Domains 1 (FHL1) and Receptor Interacting Protein of 140kda (RIP140) Interact and Cooperate in Estrogen Signaling.

Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.

Four and a Half LIM Domains 2 Contributes to the Development of Human Tongue Squamous Cell Carcinoma

FHL1 Inhibits the Progression of Colorectal Cancer by Regulating the Wnt/β-Catenin Signaling Pathway

Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-β–like signaling pathway

The Four-and-a-half-lim Protein 2 (FHL2) is Overexpressed in Gliomas and Associated with Oncogenic Activities.

Four-and-a-half-LIM protein 1 down-regulates estrogen receptor α activity through repression of AKT phosphorylation in human breast cancer cell.

The Functions of F-box Proteins in Regulating the Epithelial to Mesenchymal Transition.

Suppression of FHL2 Expression Induces Cell Differentiation and Inhibits Gastric and Colon Carcinogenesis

FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors

Mapping of FHL2 Transcription Activation Domain

FHL Family Members Suppress Vascular Endothelial Growth Factor Expression Through Blockade of Dimerization of HIF1α and HIF1β

FHL2 protein:research advances

Downregulation And Growth Inhibitory Role Of Fhl1 In Lung Cancer

Src-mediated Phosphorylation Converts FHL1 from Tumor Suppressor to Tumor Promoter